Document is current
Any future updates will be listed below
-
Authors
Kharraziha, Isabella https://orcid.org/0000-0001-9150-1289
Memarian, Ensieh
Ekblom, Örjan
Gottsäter, Anders
Engström, Gunnar
Hamrefors, Viktor
-
Funding
Funding for this research was provided by:
Livförsäkringsbolaget Skandia, Risk & Hälsa
Hjärt-Lungfonden (20230151, 2023-0248, N/A)
Research Funds at Skåne University Hospital, Region Skåne (ref number N/A) Hulda Ahlmroth Foundation (ref number N/A) Swedish Government under the LUA/ALF agreement
Vetenskapsrådet (N/A)
Crafoordska Stiftelsen (N/A)
Research Funds at Skåne University Hospital, Region Skåne (N/A) Swedish Government under the LUA/ALF agreement
- License Information
-
More Information
Article History
Received: 10 November 2024
Revised: 14 April 2025
Accepted: 25 April 2025
First Online: 5 May 2025
Competing interests
: AG has received consultancy fees from Bayer, Medtronic, Pfizer, and Sanofi. The remaining authors have no conflicts of interest to declare.
: All patients provided written informed consent. The study was approved by the regional ethical review board at Lund University (2021-01869) and all procedures were performed in accordance with the Helsinki Declaration.
